GlassScriptPhysician profile
Anthony Kelada
NPI 1659790624
$2,856.66
in general payments reported to CMS, 2019-2025
30 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.23 · 2020: $217 · 2021: $517 · 2022: $746 · 2023: $343 · 2024: $607 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $728.96 | 2021-2025 | |
| Sk Life Science, INC. | $282.70 | 2021-2025 | |
| Livanova USA, INC. | $205.24 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Pharmaceuticals, INC | $177.81 | 2021-2025 | Spravato |
| Biogen, INC. | $153.30 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $147.05 | 2024-2025 | Crexont, Rytary, Ongentys |
| Neurocrine Biosciences, INC. | $146.22 | 2022-2024 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $136.14 | 2023-2025 | Daybue |
| Neuronetics, INC. | $113.47 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $97.07 | 2022 | |
| Eisai INC. | $85.93 | 2021-2023 | |
| Lilly USA, LLC | $62.79 | 2020-2023 | Amyvid |
| Abbott Laboratories | $60.39 | 2021 | |
| Ucb, INC. | $60.30 | 2023-2024 | Fintepla |
| Lundbeck LLC | $49.10 | 2024 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $43.55 | 2023-2025 | Trintellix |
| Ultragenyx Pharmaceutical INC. | $37.48 | 2022-2025 | Dojolvi |
| Emd Serono, INC. | $35.17 | 2020 | |
| Alexion Pharmaceuticals, INC. | $25.37 | 2022 | |
| Zogenix INC. | $24.73 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.42 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.37 | 2021 | |
| Alkermes, INC. | $20.59 | 2024 | Aristada, Lybalvi |
| Novo Nordisk INC | $20.21 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.15 | 2022 | |
| Averitas Pharma INC. | $17.90 | 2024 | Qutenza |
| Almatica Pharma LLC | $15.73 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.06 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.33 | 2021 | |
| Glaxosmithkline, LLC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Kelada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.